Alderuccio JP et al. HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis. Blood Adv 2021;5(14):2852-62. Abstract
Allen P et al. Frontline treatment with single agent pembrolizumab (PEM) followed by AVD chemotherapy for classic Hodgkin lymphoma: Updated results and correlative analysis. ASH 2021;Abstract 231.
Allen PB et al. A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. Leuk Lymphoma 2020;61(7):1555-64. Abstract
Carter J et al. Current treatment options for older patients with Hodgkin lymphoma. Curr Treat Options Oncol 2020;21(5):42. Abstract
David KA et al. Real world (RW) outcomes and prognostication of older patients with primary central nervous system lymphoma (PCNSL) in the contemporary era. ASH 2020;Abstract 476.
Evens AM. Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology annual meeting and exposition: Commentary. Clin Adv Hematol Oncol 2021 Feb;19 Suppl 7(2):20-3. Abstract
Evens AM et al. Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers. Blood 2021;137(3):374-86. Abstract
Evens AM et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study. Haematologica 2021;[Online ahead of print]. Abstract
Evens AM, Parsons SK. Continuum of care for Hodgkin lymphoma: Impact of modern therapy on postacute morbidity and mortality. J Clin Oncol 2020;38(35):4131-4. Abstract
Farooq F et al. A multi-institution analysis of relapsed lymphoma occurring during pregnancy including pharmacokinetics with antenatal checkpoint inhibitor therapy. ASH 2021;Abstract 2457.
Flora DR et al. Classical Hodgkin lymphoma; Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) — a cross-sectional survey of patients with stage III or IV classical Hodgkin lymphoma compared by age. ASH 2021;Abstract 1966.
Fong AJ et al. Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey. Eur J Cancer Care (Engl) 2022;31(2):e13553. Abstract
Ha CS et al. Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: A secondary analysis of SWOG S0816. Leuk Lymphoma 2020;61(10):2442-7. Abstract
Hamid MS et al. Outcomes among classical Hodgkin lymphoma patients after an interim PET scan: A real-world experience. Clin Lymphoma Myeloma Leuk 2021:[Online ahead of print]. Abstract
Hokland P et al. How I treat advanced Hodgkin lymphoma — A global view. Br J Haematol 2020;190(6):837-50. Abstract
Kumar AJ et al. Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting. Leuk Lymphoma 2021;[Online ahead of print]. Abstract
Parsons SK et al. Classical Hodgkin lymphoma; Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT): Observations of physicians on treatment and interim PET-adapted regimens. ASH 2021;Abstract 1390.
Olszewski AJ et al. Burkitt lymphoma international prognostic index. J Clin Oncol 2021;39(10):1129-38. Abstract
Olszewski AJ et al. Outcomes of Burkitt lymphoma (BL) managed in academic (acad) or community (comm) centers: Real-world evidence (RWE) from 30 US sites. ASCO 2020;Abstract 8043.
Shah MR et al. Lymphoma occurring during pregnancy: Current diagnostic and therapeutic approaches. Curr Oncol Rep 2020;22(11):113. Abstract
Torka P et al. Treatment strategies for advanced classical Hodgkin lymphoma in the times of dacarbazine shortage. JCO Oncol Pract 2022;[Online ahead of print]. Abstract
Zayac AS et al. Outcomes of Burkitt lymphoma with central nervous system involvement: Evidence from a large multicenter cohort study. Haematologica 2021;106(7):1932-42. Abstract